Genentech Inc. (DNA) is in the Pharma Industry

• Sort by

• Genentech, Biogen Shares Drop After Lupus Study Fails

  CHICAGO (Reuters) - Genentech Inc DNA and Biogen Idec Inc BIIB said on Tuesday a key study of Rituxan did not meet its main goal of a response in patients with systemic lupus erythematosus, commonly called lupus. The Phase II/III study also did...

  News items 2008-04-29

  Tags: Biogen Idec Inc., Genentech Inc., patient, Chicago, DNA, Thomson Reuters Corp., stock, sales

• Roche Sales, Stock Hit By Tamiflu Slump

  By Sam Cage ZURICH (Reuters) - Roche Holding AG ROG missed forecasts with a meager 2 percent increase in first-quarter sales in local currencies, hit by plunging Tamiflu revenue and a slowing pace of growth for cancer drugs. Its stock fell 3.5 percent...

  News items 2008-04-17

  Tags: Sales strategy, Sales force management, Investment, Roche Holding AG, Zurich, drug company, pharmaceutical company, sales, stock, Thomson Reuters Corp., earnings forecast, revenue, government, biotechnology, DNA, trader, analyst, stock price, U.S., partnership, pricing strat

Additional Resources

• Curis Announces Genentech's Initiation of Hedgehog Antagonist Phase II Clinical Trial In Metastatic Colorectal Cancer

  Trial tests oral administration of GDC-0449 in combination with bevacizumab and a standard chemotherapy regimen CAMBRIDGE, Mass. -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, today announced that its collaborator Genentech has initiated a...

  Articles 2008-05-05

• ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2008 Financial Results

  Highlights Continued Progress with Numerous Clinical Anticancer Compounds WALTHAM, Mass. -- ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug TAP technology, today announced financial results for the three-month period ended March 31, 2008 - the third quarter of the Company's...

  Articles 2008-05-01

• Slalom Consulting Strengthens Leadership Team in San Francisco

  Slalom Consulting, rankedone of the best consulting firms to work for in the U.S., today announcedthe appointment of three new account managers, Steve George, Carl Johnsonand David Van Diggelen, at the firm's rapidly growing San Francisco BayArea office. The new team leaders will support further market growth asSlalom widens its...

  Articles 2008-04-29

• Genentech and Biogen Idec Announce Top-Line Results from Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus

  SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass. -- Genentech, Inc. (NYSE:DNA) and Biogen Idec, Inc. (Nasdaq:BIIB) announced today that a Phase II/III study of Rituxan([R])rituximab for systemic lupus erythematosus (SLE, commonly called lupus) did not meet its primary endpoint defined as the proportion of Rituxan treated patients who achieved a...

  Articles 2008-04-29

• Seven Summits Research Releases Alerts on COP, MA, DNA, IR, and MVSN

  CHICAGO, April 29 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for key stocks. Seven Summits Strategic Investments' PriceWatch Alerts are available at http://www.iotogo.com/s/042908A (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's PriceWatch Alerts...

  Articles 2008-04-29

• Flashpoint Medica Named Agency of Year by Medical Advertising News

  Innovative Thinking, Powerful Creative Drive Success NEW YORK, April 29 /PRNewswire/ -- Flashpoint Medica, a full-service advertising and brand-development firm and member of the Omnicom Group , was named Agency of the Year, Category III by Medical Advertising News at the publication's annual Manny Awards ceremony held...

  Articles 2008-04-29

• Zacks Analyst Blog Highlights: Amgen, Genentech, Biogen Idec, Genzyme and Gilead Sciences

  CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amgen, Inc. (Nasdaq: AMGN), Genentech Inc. (NYSE: DNA), Biogen Idec, Inc....

  Articles 2008-04-28

• Curis to Present at Deutsche Bank 33rd Annual Healthcare Conference

  CAMBRIDGE, Mass. -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the Deutsche Bank 33rd Annual Health Care Conference, which is being held on May 5-7, 2008 in...

  Articles 2008-04-28

• Janitors rally for wages, health care in Foster City

  FOSTER CITY -- Dozens of janitors marched Thursday at the Metro Center, calling for better wages and health care and threatening a strike next month if they don't get them. Chanting "contract now," the janitors took to the streets of Foster City as part of an...

  Articles 2008-04-25

• Genentech Announces Decision in Contract Dispute

  -- California Supreme Court Reverses $200 Million Punitive Damages Award -- SOUTH SAN FRANCISCO, Calif. -- Genentech, Inc. (NYSE:DNA) today announced that the California Supreme Court has overturned the award of $200 million in punitive damages resulting from a contract dispute brought by the City of Hope National...

  Articles 2008-04-24

• Curis to Release First Quarter 2008 Financial Results and Hold Conference Call on April 30, 2008

  CAMBRIDGE, Mass. -- Curis, Inc. (NASDAQ:CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment, today announced that it will release its first quarter financial results on Wednesday, April 30, 2008 before the market opens. The Company will also hold a conference call on the...

  Articles 2008-04-23

• Women business founders are on the rise, but not in 'Fortune' 1000

  Where are the Starbucks, Nikes, Amazons, Home Depots and Genentechs founded by women? This is a question that puzzles those who track fast-growing companies. Few fledgling businesses founded by men or women ever grow into giant corporations, but with women launching twice as many businesses as men, some...

  Articles 2008-04-23

• Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer

  Avastin Used in Combination with Taxol and Paraplatin Will Become the Clinical Gold Standard Treatment by 2011, According to a New Report from Decision Resources WALTHAM, Mass., April 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare...

  Articles 2008-04-23

• NCCN Updates Non-Hodgkin's Lymphoma Guidelines

  FORT WASHINGTON, Pa. -- The National Comprehensive Cancer Network NCCN announces several new updates to the NCCN Clinical Practice Guidelines in Oncology[TM] Non-Hodgkin's Lymphoma NHL. These changes highlight leading developments in the treatment of NHL and represent the recognized standard for clinical care in oncology in both the community and...

  Articles 2008-04-22

• Genentech Provides Update on "AVAiL" Phase III Study of Avastin Plus Chemotherapy in First-Line, Advanced, Non-Squamous, Non-Small Cell Lung Cancer

  SOUTH SAN FRANCISCO, Calif. -- Genentech, Inc. (NYSE:DNA) today announced an update for the previously reported Roche-sponsored international Phase III clinical study AVAiL of Avastin([R]) bevacizumab in combination with gemcitabine and cisplatin chemotherapy, in patients with advanced, non-squamous, non-small cell lung cancer NSCLC. The update confirmed the clinically and statistically...

  Articles 2008-04-21

• Cancer Treatment Pioneer, Lpath, Initiates Dosing in Phase 1 Cancer Trial

  Lpath, Inc. (OTCBB: LPTN), the categoryleader in bioactive-lipid-based therapeutics, initiated its first Phase 1clinical trial on April 16, 2008 by dosing a cancer patient with its leaddrug candidate, ASONEPTM, a monoclonal antibody targetingsphingosine-1-phosphate ("S1P"). ASONEP is the systemic version ofsonepcizumab and the humanized version of SphingomabTM. "We view this...

  Articles 2008-04-21

• VioQuest Pharmaceuticals' Novel Akt Inhibitor VQD-002 is Synergistic with Various Cancer Therapies in Preclinical Studies

  Results presented at the Annual Meeting of American Association for Cancer Research AACR BASKING RIDGE, N.J. -- VioQuest Pharmaceuticals (OTCBB: VQPH) today announced preclinical data demonstrating that the company's novel AKT inhibitor VQD-002 delivers synergistic benefit in combination with a range of cancer therapies including trastuzumab (Herceptin[R]; Genentech,...

  Articles 2008-04-16

• Danong Chen appointed CEO of Theranostics Health

  ROCKVILLE, Md., April 16 /PRNewswire/ -- The Board of Managers of Theranostics Health, LLC, is pleased to announce that Dr. Danong Chen has been elected as the new President and CEO of Theranostics Health. Dr. Chen was previously the President and CEO of Tanox Inc., a publicly held biopharmaceutical...

  Articles 2008-04-16